
Quarterly ResultMay 6, 2026, 12:41 PM
AtriCure Q1 Net Income $108K; Revenue Jumps 14.3% to $141.2M
AI Summary
AtriCure, Inc. reported a net income of $108,000 for the first quarter of 2026, a significant improvement from a net loss of $6.7 million in the prior year. Total revenue increased by 14.3% to $141.2 million, driven by strong growth in pain management and open ablation products. The company also amended its asset-based credit facility, extending its term to 2029 and reducing the interest rate. Legal proceedings related to the SentreHEART acquisition continue, with a claim for up to $260 million in damages.
Key Highlights
- AtriCure reported net income of $108,000 for Q1 2026, compared to a net loss of $6.7 million in Q1 2025.
- Total revenue increased 14.3% to $141.2 million in Q1 2026 from $123.6 million in Q1 2025.
- Basic and diluted EPS improved to $0.00 in Q1 2026 from $(0.14) in Q1 2025.
- US pain management revenue grew 29.5% to $22.4 million; US open ablation revenue rose 17.3% to $39.1 million.
- Net cash used in operating activities improved to $(4.0) million from $(11.0) million year-over-year.
- The asset-based credit facility was amended, extending maturity to January 2029 for $61.0 million debt.
- The company faces a lawsuit seeking up to $260.0 million in damages related to the SentreHEART acquisition.
Price Impact
More from ATRC